Lumretuzumab (RG7116, RO5479599) is a glycoengineered anti-HER3 antibody, which impairs HRG binding to HER3 and induces antibody dependent cytotoxicity in preclinical models.[136] Efficacy has been demonstrated in experimental models of HNSCC.[137] A recent phase I study proved the safety of RG7116 in patients with HER3-positive advanced solid tumors and showed stable disease in 21.3% or patients and partial response in 23.7% of patients (Table 5).[138]. The gene discussed is ERBB3; the disease is head and neck squamous cell carcinoma.